
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc. is positioned favorably with its focus on developing therapies for orphan pulmonary and fibrosis indications, highlighted by its Phase 2-ready assets, LTI-03 and LTI-01, which target unmet medical needs in Idiopathic Pulmonary Fibrosis and loculated pleural effusion, respectively. The observed increase in sRAGE levels in LTI-03 trial participants indicates a positive pharmacodynamic response, reinforcing the product's potential effectiveness. Furthermore, the company's promising pipeline and favorable risk-reward profile could lead to significant market opportunities, especially if it successfully extends its cash runway to support ongoing clinical development.
Bears say
Rein Therapeutics Inc. has experienced a significant decline in its stock value, with shares falling 50% year to date in 2025, contrasting sharply with the 3.5% gain of the XBI index. The company's decision to pause patient enrollments in its U.S. clinical trials has contributed to heightened uncertainty, negatively impacting investor confidence. Additionally, clinical findings suggest that lower levels of soluble Receptor for Advanced Glycation End-products (sRAGE) correlate with poor survival rates in patients with Idiopathic Pulmonary Fibrosis (IPF), raising further concerns regarding the efficacy of its product candidates in this indication.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares